BRIDGEBIO PHARMA INC (BBIO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BBIO • US10806X1028

68.05 USD
+4.32 (+6.78%)
At close: Feb 6, 2026
68.05 USD
0 (0%)
After Hours: 2/6/2026, 6:20:56 PM
Fundamental Rating

3

Overall BBIO gets a fundamental rating of 3 out of 10. We evaluated BBIO against 524 industry peers in the Biotechnology industry. BBIO may be in some trouble as it scores bad on both profitability and health. BBIO is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BBIO had negative earnings in the past year.
  • In the past year BBIO has reported a negative cash flow from operations.
  • BBIO had negative earnings in each of the past 5 years.
  • In the past 5 years BBIO always reported negative operating cash flow.
BBIO Yearly Net Income VS EBIT VS OCF VS FCFBBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

  • With a Return On Assets value of -79.85%, BBIO is not doing good in the industry: 67.75% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -79.85%
ROE N/A
ROIC N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBIO Yearly ROA, ROE, ROICBBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • Looking at the Gross Margin, with a value of 95.78%, BBIO belongs to the top of the industry, outperforming 95.80% of the companies in the same industry.
  • BBIO's Gross Margin has been stable in the last couple of years.
  • BBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
BBIO Yearly Profit, Operating, Gross MarginsBBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • BBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BBIO has more shares outstanding than it did 1 year ago.
  • BBIO has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BBIO has been reduced compared to a year ago.
BBIO Yearly Shares OutstandingBBIO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BBIO Yearly Total Debt VS Total AssetsBBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of -3.44, we must say that BBIO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -3.44, BBIO perfoms like the industry average, outperforming 45.99% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.44
ROIC/WACCN/A
WACC8.46%
BBIO Yearly LT Debt VS Equity VS FCFBBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • BBIO has a Current Ratio of 3.88. This indicates that BBIO is financially healthy and has no problem in meeting its short term obligations.
  • BBIO's Current ratio of 3.88 is in line compared to the rest of the industry. BBIO outperforms 46.56% of its industry peers.
  • A Quick Ratio of 3.76 indicates that BBIO has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.76, BBIO is in line with its industry, outperforming 47.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.76
BBIO Yearly Current Assets VS Current LiabilitesBBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • BBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -57.74%.
  • The Revenue has grown by 62.46% in the past year. This is a very strong growth!
  • Measured over the past years, BBIO shows a very strong growth in Revenue. The Revenue has been growing by 40.48% on average per year.
EPS 1Y (TTM)-57.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
Revenue 1Y (TTM)62.46%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%4318.01%

3.2 Future

  • The Earnings Per Share is expected to grow by 34.99% on average over the next years. This is a very strong growth
  • BBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 69.42% yearly.
EPS Next Y-14.85%
EPS Next 2Y17.7%
EPS Next 3Y28.28%
EPS Next 5Y34.99%
Revenue Next Year127.06%
Revenue Next 2Y101.58%
Revenue Next 3Y91.44%
Revenue Next 5Y69.42%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBIO Price Earnings VS Forward Price EarningsBBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBIO Per share dataBBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BBIO's earnings are expected to grow with 28.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.7%
EPS Next 3Y28.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (2/6/2026, 6:20:56 PM)

After market: 68.05 0 (0%)

68.05

+4.32 (+6.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29
Earnings (Next)02-19
Inst Owners91.39%
Inst Owner Change-0.62%
Ins Owners4.09%
Ins Owner Change-16.43%
Market Cap13.11B
Revenue(TTM)353.78M
Net Income(TTM)-797.12M
Analysts85.38
Price Target90.56 (33.08%)
Short Float %11.03%
Short Ratio7.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.62%
Min EPS beat(2)-10.44%
Max EPS beat(2)-4.81%
EPS beat(4)1
Avg EPS beat(4)-7.51%
Min EPS beat(4)-21.38%
Max EPS beat(4)6.56%
EPS beat(8)3
Avg EPS beat(8)11.85%
EPS beat(12)3
Avg EPS beat(12)2.94%
EPS beat(16)5
Avg EPS beat(16)7.09%
Revenue beat(2)2
Avg Revenue beat(2)14.91%
Min Revenue beat(2)11.23%
Max Revenue beat(2)18.58%
Revenue beat(4)4
Avg Revenue beat(4)45.04%
Min Revenue beat(4)11.23%
Max Revenue beat(4)84.61%
Revenue beat(8)5
Avg Revenue beat(8)176.66%
Revenue beat(12)5
Avg Revenue beat(12)105%
Revenue beat(16)6
Avg Revenue beat(16)88%
PT rev (1m)5.56%
PT rev (3m)27.32%
EPS NQ rev (1m)3.39%
EPS NQ rev (3m)4.92%
EPS NY rev (1m)0.14%
EPS NY rev (3m)-2.67%
Revenue NQ rev (1m)2.73%
Revenue NQ rev (3m)4.87%
Revenue NY rev (1m)0.66%
Revenue NY rev (3m)6.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.18
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-3.1
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS1.84
BVpS-10.03
TBVpS-10.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.78%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)-74.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.94%
GM growth 5Y0.92%
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 238.46%
Cap/Sales 3.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.76
Altman-Z -3.44
F-Score4
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)86.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)8.73%
Cap/Sales(5y)27.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.64%
EPS Next Y-14.85%
EPS Next 2Y17.7%
EPS Next 3Y28.28%
EPS Next 5Y34.99%
Revenue 1Y (TTM)62.46%
Revenue growth 3Y47.1%
Revenue growth 5Y40.48%
Sales Q2Q%4318.01%
Revenue Next Year127.06%
Revenue Next 2Y101.58%
Revenue Next 3Y91.44%
Revenue Next 5Y69.42%
EBIT growth 1Y-11.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.31%
EBIT Next 3Y33.72%
EBIT Next 5Y24.11%
FCF growth 1Y-20.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.87%
OCF growth 3YN/A
OCF growth 5YN/A

BRIDGEBIO PHARMA INC / BBIO FAQ

What is the fundamental rating for BBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to BBIO.


What is the valuation status for BBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIDGEBIO PHARMA INC (BBIO). This can be considered as Overvalued.


Can you provide the profitability details for BRIDGEBIO PHARMA INC?

BRIDGEBIO PHARMA INC (BBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for BBIO stock?

The financial health rating of BRIDGEBIO PHARMA INC (BBIO) is 3 / 10.